Lisa Ferdinando
Diluted earnings per share for January-March were $0.86 compared to $0.6 a year earlier. The adjusted figure was $0.93 with a forecast of $0.77. Pfizer's revenue for the quarter also rose 1.5 times to $14.582 billion. Analysts had expected revenue of $13.67 billion.
The company also improved its revenue forecast for the current year to $70.572.5 billion, previously the figure was expected to be $59.4-61.4 billion. Adjusted diluted earnings per share in 2021 will be $3.55-3.65, the company forecasts, previously expecting $3.1-3.2.
Pfizer also improved its revenue forecast for the COVID-19 vaccine (BNT162b2) to $26 billion from the previously expected $15 billion.
Pfizer Inc. was founded in the U.S. in 1849 and is now one of the global leaders in the pharmaceutical industry. The company is headquartered in New York and has its main research centre in Groton, Connecticut.
source: bloomberg.com
The company also improved its revenue forecast for the current year to $70.572.5 billion, previously the figure was expected to be $59.4-61.4 billion. Adjusted diluted earnings per share in 2021 will be $3.55-3.65, the company forecasts, previously expecting $3.1-3.2.
Pfizer also improved its revenue forecast for the COVID-19 vaccine (BNT162b2) to $26 billion from the previously expected $15 billion.
Pfizer Inc. was founded in the U.S. in 1849 and is now one of the global leaders in the pharmaceutical industry. The company is headquartered in New York and has its main research centre in Groton, Connecticut.
source: bloomberg.com
